Introduction
One characteristic of many autoimmune diseases such as serum antibody to nuclear antigens such as snRNPs, histones and double-stranded (ds) DNA, and their kidneys showed systemic lupus erythematosus (SLE) is the presence of specific autoantibodies that are absent in non-autoimmune evidence of immune complex glomerulonephritis (7). It should be noted that another bcl-2 lineage (M23) did not show this individuals. A breakdown in the regulation of autoreactive B lymphocytes could occur at multiple levels, including in the phenomenon (8). It has been suggested that the relevant parameter distinguishing these two bcl-2 transgenics was generation of the initial repertoire in the bone marrow (BM) (by blocking deletion or anergy) or in the formation of the their genetic background (C57BL/6ϫSJL for bcl-2-22 and C57BL/6 for M23) (9). modified repertoire during germinal center (GC) maturation. In the latter case, autoantibodies may arise as a result of To address the role that altered Bcl-2 expression could have on B cell tolerance, several groups have used these somatic mutation of non-autoreactive B cells. Generally these autoreactive B cells would die in the absence of T help to a bcl-2 transgenic mice in conjunction with Ig transgenic mice.
In the anti-erythrocyte and anti-MHC class I tolerance models, new antigen (reviewed in 1). Death due to lack of a positive signal is often referred to as death by neglect (2). This would Bcl-2 was shown to block peripheral deletion of autoreactive B cells, while leaving deletion in the BM intact (10,11). In predict then, if death by neglect is blocked, autoantibodies would be produced.
contrast, in the anti-hen egg lysozyme (HEL)/mHEL model, Bcl-2 did permit the export of autoreactive B cells from the Bcl-2 has been shown to protect lymphocytes from some forms of death by neglect, including growth factor with-BM that would otherwise have been deleted. Importantly however, the cells that escaped deletion were left functionally drawal (3). Furthermore, Bcl-2 is implicated in B lymphocyte repertoire selection by its tightly regulated pattern of expresinactive; thus B cell tolerance was maintained (12). Likewise, in the anti-HEL/sHEL anergy model, aberrant expression of sion: Bcl-2 is not expressed during times of B cell selection, including pre-B and immature B cells in the BM and GC B Bcl-2 did not overcome the functional inactivation of the autoreactive B cells (13). Together, these experiments suggest cells (4-6). Consistent with this, some bcl-2 transgenic mice (bcl-2-22) develop a fatal autoimmune disease. This disease that the presence of a bcl-2 transgene (Tg), while blocking peripheral deletion, does not affect B cell tolerance initiated was reported to resemble SLE in that the mice developed VH3H9 transgenic mice, we have shown that in the nonautoimmune BALB/c background, anti-dsDNA B cells are actively tolerized as manifested by their developmental arrest, localization to the T/B interface in the spleen, increased in vivo turnover rate and lack of serum autoantibody (17) . In autoimmune-prone MRL-lpr/lpr mice, this tolerance breaks down: anti-dsDNA B cells are no longer developmentally arrested nor held at the T/B interface and by 10 weeks of age their antibody is in the serum (18) . Here, we show that Bcl-2 extends the lifespan of anti-dsDNA B cells in VH3H9 transgenic mice, but does not inhibit other manifestations of B cell tolerance. Therefore, increasing a B cell's lifespan is asterisk. bcl-2: 2-4 months, n ϭ 14, 5-8 months, n ϭ 42, 9-15 months, n ϭ 28; VH3H9/bcl-2: 2-4 months, n ϭ 18, 5-8 months, n ϭ 26, 9-15 months, n ϭ 14; Tg(-): 2-4 months, n ϭ 24, 5-8 months,
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n ϭ 48, 9-15 months, n ϭ 12; VH3H9: 2-4 months, n ϭ 19, 5-8 months, n ϭ 26, 9-15 months, n ϭ 15.
Mice
BALB/c mice were purchased from Harlan Sprague-Dawley (Indianapolis, IN). MRL-lpr/lpr and C57BL/6-lpr/lpr mice were purchased from Jackson Laboratory (Bar Harbor, ME). To generate the bcl-2 transgenic mice used in this study (bcl-2 line 6), human bcl-2 was placed under control of the IgH chain intron enhancer, with the intention of directing expression to lymphocytes (15) . bcl-2 line 6 transgenic mice, originally on the SWR background, and VH3H9 transgenic mice (14) have been backcrossed for four to 10 generations onto the BALB/c background. No difference was detected between early and late backcross mice for the parameters tested. The mice have been bred and maintained in a separate specific pathogen-free room at The Wistar Institute animal facility. In all cases, age-matched BALB/c mice or non-transgenic littermates, housed similarly, were used as controls. The presence of the bcl-2 and VH3H9 Tgs was determined by PCR amplification of tail DNA with primers specific for human The VH3H9 H chain transgenic has been shown to be a for three parameters: glomerulonephritis, interstitial nephritis and good excluder of endogenous H chain rearrangement in the vasculitis. The grades for the three parameters were then combined BALB/c background (14) , and the lack of endogenous H to give an overall disease severity score. Individual mice are represented by circles and the average disease severity for each chain in the IgM only VH3H9 transgenic mice was confirmed genotype is indicated by an asterisk.
here by the lack of staining for IgD and IgG (data not shown). VH3H9 when paired with Igλ1 generates an anti-dsDNA Ig and we have followed the fate of anti-dsDNA B cells in VH3H9 transgenic mice using anti-Igλ-specific reagents (17) . Several in the BM. None of these experiments, however, addressed the fate of B cells with specificities that arise spontaneously different reagents were used to track Igλ ϩ and Igλ1 ϩ B cells (LS136, R11-153, JC5 and R26-46). Using these reagents in bcl-2 transgenic mice, i.e. anti-nuclear antibodies (ANA).
To determine where B cell tolerance to nuclear antigens and flow cytometry we have shown that the majority (79 Ϯ 19%) of Igλ ϩ B cells in VH3H9 and VH3H9/bcl-2 breaks down in bcl-2 transgenic mice, we have used VH3H9 Ig transgenic mice (14) . These mice allow us to identify and transgenic mice are Igλ1, as they are from Tg(-) mice (17 and data not shown). Therefore, we are able to follow VH3H9/λ1 track anti-dsDNA B cells in the context of a bcl-2 Tg (bcl-2 line 6 transgenic mice) (15 indicating that multiple L chain rearrangements had occurred Birmingham, AL); and streptavidin-Red670 (Gibco/BRL, Gaithersburg, MD). (16) . Unlike the Igλ ϩ B cells in bcl-2 transgenic mice, the majority of Igλ ϩ B cells in VH3H9/bcl-2 transgenic mice do All samples were analyzed on a FACScan flow cytometer (Becton Dickinson, Mountain View, CA) using CellQuest softnot co-express an Igκ L chain as assessed by flow cytometry (5.2 Ϯ 2.5% co-express Igκ and Igλ). Furthermore, isotype ware. In total, 40,000 events, gated for live lymphocytes based on forward and side scatter, were collected for each sample. analysis of hybridomas generated from VH3H9/bcl-2 BALB/c mice confirmed the presence of Igλ ϩ B cells that exclusively BrdU labeling express an Igλ L chain (data not shown). The fact that the majority of Igλ ϩ B cells in VH3H9 transgenic mice do not coMice were injected i.p. with 200 µl of 3 mg/ml BrdU (Sigma) in PBS every 12 h for 8 days. BrdU staining was performed express Igκ is what allows us to use Igλ-specific reagents to identify anti-dsDNA B cells in VH3H9 transgenic mice without essentially as described (20) , with the exception that the cells were not fixed in ethanol. Briefly, spleen and BM cells from the concern that we are following VH3H9/λ/κ ϩ cells which may have an altered specificity.
mice were isolated and surface stained as described above. The cells were then fixed and permeabilized with 1% Flow cytometry analysis paraformaldehyde containing 0.1% Tween 20. The DNA was denatured using 10 µM HCl and 100 U/ml DNase I. The Cells (5ϫ10 5 ) were surface stained according to standard protocols (19) . The following antibodies were used: RA3-6B2-incorporated BrdU was then detected using an anti-BrdU-FITC antibody (B44) from Becton Dickinson and cells analyzed phycoerythrin (PE) or -biotin (anti-B220), R11-153-FITC (antiIgλ1), R26-46-FITC or -biotin (anti-Igλ total), R8-140-PE by flow cytometry as described above. The spleen sections were stored at -20°C and then stained according to the protocol described (21) . Briefly, the sections IgG-FITC (Sigma, St Louis, MO), polyclonal anti-IgM-PE and SBA-1-PE (anti-IgD) (Southern Biotechnology Associates, were blocked using PBS/5% normal goat serum/0.1% Tween separated based on GC size: small (10-29 cells in diameter) and large (Ͼ30 cells in diameter) to equalize for the frequency of non-apoptotic cells. No difference was detected in the number of small GC versus large GC for Tg(-) and bcl-2 transgenic mice.
Hybridoma generation and Ig sequence analysis
Unmanipulated spleen cells from a bcl-2 transgenic mouse (age 7.5 months, serum ANA ϩ ) and two VH3H9/bcl-2 transgenic mice (ages 7 weeks and 5.5 months, both serum ANA -) were fused to the Ig -myeloma, Sp2/0. To ensure that any clones detected were not due to expansion in vitro, cells were immediately plated at limiting dilution and wells bearing single colonies were expanded for analysis. The H and L chain V regions were sequenced from mRNA according to the The Ig isotype of hybridomas was determined via an indirect solid-phase ELISA assay, using anti-IgH ϩ L (Southern Biotechnology Associates) as the primary antibody and develop-20, and then stained with GK1.5-biotin (anti-CD4), 53-6.7-ing with AP-labeled anti-IgM, -IgG, -Igκ or -Igλ antibodies biotin (anti-CD8), RA3-6B2-biotin (anti-B220) (grown as (Southern Biotechnology Associates). supernatants) and/or anti-Igλ-alkaline phosphatase (AP; Southern Biotechnology Associates). Apoptosis was deterSouthern blots mined using an in situ cell death detection kit (Boehringer DNA was prepared from hybridoma cell cultures using Mannheim, Indianapolis, IN) according to manufacturer's proteinase K digestion followed by phenol extraction. Then instructions, with the exception that the slides were fixed with 10 µg of DNA was digested with either EcoRI or BamHI, size acetone prior to fixing in 4% paraformaldehyde to optimize separated, and blotted onto Zeta-probe blotting membrane surface antigen staining. The sections were then stained (BioRad, Richmond, CA). DNA rearrangements at the H chain with peanut agglutinin (PNA)-biotin (Vector, Burlingame, CA).
locus were detected by probing EcoRI-digested DNA with TUNEL staining (dUTP-FITC) was detected with anti-FITCpJ11 (23) and rearrangements at the L chain locus were AP (Sigma). Streptavidin-horseradish peroxidase (HRP) or analyzed by probing BamHI-digested DNA using the pECK -AP (Southern Biotechnology Associates) was used as a probe (24) . secondary antibody with the biotinylated reagents. HRP and AP were developed using the substrates 3-amino-9-ethyl-ANA assay carbazole and Fast-Blue BB base (Sigma) respectively.
The presence of ANA in serum and supernatants was detected Quantification of apoptotic GC B cells in situ using permeabilized HEP-2 cells as the substrate following the manufacturer's instructions (Antibodies Incorporated, Davis, TUNEL-stained spleen sections from influenza-immunized mice were analyzed for the number of apoptotic cells per CA). Serum giving a homogeneous nuclear (HN) staining pattern was defined as ANA ϩ . This pattern is found in a high GC. Sections were counted in a blind fashion by three separate investigators. The ratio of apoptotic cells in Tg (-) frequency of SLE serum, and correlates with the presence of anti-dsDNA, anti-histone and/or anti-chromatin antibodies and bcl-2 transgenic GC was consistent among the three readers. At least 40 GC were counted per spleen and were (25) . Serum ANA titers were determined for a subset of the ANA ϩ mice. The serum samples were tested at an initial supernatants were used undiluted. ANA binding was detected using anti-mouse IgM ϩ IgG or Igλ-FITC secondary anti-1:100 dilution and at serial 10-fold dilutions. The serum titer was defined as the reciprocal of the last dilution at which bodies (Southern Biotechnology Associates). The samples were visualized under a fluorescent microscope and scored positive staining was seen (data not shown). B cell hybridoma in a blind fashion without knowledge of genotype or age of the mice. infiltrates and intimal hyperplasia. Grades for the three para-meters were combined to give a total score for disease results using another bcl-2 transgenic model (bcl-2-22) which also developed ANA and kidney pathology (7). Notably, the severity. All sections were graded in a blind fashion without knowledge of age or genotype of the mice. extent of pathology observed in the bcl-2 transgenic mice is lower than in diseased MRL-lpr/lpr mice (Fig. 2) .
Fas ligand (FasL) production
To directly assess the impact of aberrant Bcl-2 expression on anti-dsDNA B cells, we took advantage of the VH3H9 Ig COS7 cells were transfected with pEF-mFLWX1 (murine FasL transgenic model. As a Tg, VH3H9 can pair with a variety of expression plasmid) (27) using Lipofectamine (Gibco/BRL) different L chains to generate both anti-DNA and non-DNA as follows. COS7 (1ϫ10 5 ) cells were seeded into 35 mm antibodies (30, 31) . In particular, VH3H9 pairs with the Igλ1 L dishes and incubated for 18 h. For transfection, 2 µg of DNA chain to generate an anti-dsDNA antibody (30, 32) , thus and 10 µl of Lipofectamine were used to form liposome-DNA enabling us to use anti-Igλ-specific reagents to follow anticomplexes, transferred to washed 35 mm dishes of COS7 dsDNA B cells in a diverse repertoire. Previously we have cells in a volume of 800 µl and incubated 4 h. The transfected shown for another mouse model of SLE, the MRL-lpr/lpr cells were washed once in PBS, normal media added, and mouse, that the presence of the VH3H9 Tg does not alter the incubated for 48 h at 37°C and 5% CO 2 . Supernatants kinetics of seroconversion. Furthermore, VH3H9/λ anti-dsDNA containing soluble FasL were collected, cleared by centrifugaantibodies are detected in the serum when the MRL-lpr/lpr tion at 1000 g for 10 min and stored at -70°C prior to use. mice become ANA ϩ (18) . In contrast, the VH3H9 Tg reduces
Apoptosis of GC B cells
ANA production in bcl-2 transgenic mice (Fig. 1) . Even in those mice that were ANA ϩ , generally Igλ ϩ antibody did not Influenza virus immunization was performed as described contribute to the serum ANA; Igλ ANA staining was not (22) . Briefly, Tg(-) BALB/c and bcl-2 transgenic BALB/c mice detected in the serum of Ͼ98% of VH3H9/bcl-2 mice (n ϭ were immunized i.v. with 1000 HAU of PR8 virus in 200 µl 58, ages 2-15 months). Consistent with the reduction in serum volume of PBS. Eight days later spleens and thymi were ANA, VH3H9/bcl-2 mice exhibit less nephritis than bcl-2 Tg removed and cultured for 4 h in either media alone, FasLalone mice (Fig. 2) . transfected supernatant or mock-transfected supernatant. No difference was detected between media and mock trans-
bcl-2 Tg increases the lifespan of anti-dsDNA B cells fected supernatant, and therefore media was used in most
To determine if the bcl-2 Tg increased the in vivo lifespan of experiments. Thymocytes from lpr/lpr mice, which are defi-VH3H9/λ B cells, Tg(-), VH3H9 and VH3H9/bcl-2 BALB/c cient in Fas (28, 29) , were used as a negative control for Fasmice were labeled with BrdU for 8 days, and the incorporation mediated killing. After culture, the cells were then harvested of BrdU into their splenic B cell populations was measured. and stained for the presence of apoptotic cells using Annexin
To assess the lifespan of the anti-dsDNA population of cells, V-FITC (PharMingen). The spleen cells were then stained BrdU incorporation in the Igλ ϩ subset was evaluated. Among with PNA-biotin (Vector) and B220-PE (PharMingen) to mark the Igλ ϩ cells, the frequency of BrdU ϩ cells is higher in the GC B cells and analyzed by flow cytometry as described VH3H9 transgenic mice than in the Tg(-) mice (63.1 Ϯ 5.6 above.
versus 9.5 Ϯ 4.0%), suggesting that the anti-dsDNA B cells Statistical analysis have a decreased in vivo lifespan (Fig. 3) (17) . However, in the presence of the bcl-2 Tg, only 13.1 Ϯ 1.3% of the VH3H9/ Statistical significance was determined using an unpaired λ B cells were labeled. This indicates that the bcl-2 Tg does non-parametric test or a Student's t-test and Instat Software.
increase the lifespan of VH3H9/λ B cells. Consistent with this increase in lifespan, Bcl-2 increases the frequency of Igλ ϩ B Results cells in the BM, spleen and lymph node (LN) compared to that in VH3H9 transgenic mice without the bcl-2 Tg (Fig. 4) .
ANA production and nephritis in bcl-2 transgenic mice
In VH3H9 transgenic mice without the bcl-2 Tg, the frequency of Igλ ϩ B cells decreases between the spleen and LN. In To determine if the bcl-2 line 6 transgenic mice expressed ANA, serum from age-matched Tg(-) and bcl-2 transgenic contrast, in VH3H9/bcl-2 transgenic mice, this decrease is not apparent (Figs 3 and 4) , suggesting that an increased BALB/c mice were evaluated. In bcl-2 transgenic mice, the frequency of mice expressing serum ANA is increased comlifespan allows the anti-dsDNA B cells to circulate to the LN. pared to Tg(-) BALB/c mice and also increases with the age Bcl-2 does not alter the surface phenotype or splenic of the mice (Fig. 1) . This is similar to what has been reported localization of anti-dsDNA B cells for bcl-2-22 transgenic mice (7), but different from another bcl-2 transgenic line (M23), which was reported to be To determine if an increased lifespan has an effect on the phenotype of the anti-dsDNA VH3H9/λ B cells, we used flow ANA -(8). Whether unique aspects of the constructs and hence the expression pattern of the bcl-2 Tgs, or the genetic cytometry and an anti-Igλ reagent to characterize the antidsDNA B cells. The level of Ig on the surface of VH3H9/λ B background on which the Tgs were studied, accounts for these differences has not been determined.
cells is down-regulated in the periphery compared to the Igλ ϩ B cells from Tg(-) mice and Bcl-2 does not change this Kidneys from 2-to 8-month-old Tg(-) and bcl-2 line 6 BALB/c mice exhibited no significant kidney pathology (Fig. 5a ). Interestingly, the Ig level is also decreased on the Igλ ϩ B cells from the BM. This decreased Ig density suggests (data not shown). In older mice (9-15 months old), however, bcl-2 transgenic mice exhibited significant nephritis comthat these cells have encountered their antigen initially in the BM and that Bcl-2 does not affect the timing of this encounter. pared to Tg(-) BALB/c mice (Fig. 2) . This is similar to the To assess if aberrant expression of Bcl-2 translates into levels of B220, CD21/35, CD22 and CD23, and an increased level of HSA. other changes in surface phenotype, we compared the levels of a panel of developmental markers (B220, HSA, CD21/35, We next addressed whether increasing the lifespan of the anti-dsDNA B cells altered their splenic localization. In Tg(-) CD22 and CD23) (19, 20, (33) (34) (35) on splenic VH3H9/λ B cells with and without the bcl-2 transgenic. In the spleen, VH3H9/ BALB/c mice, Igλ ϩ B cells are located primarily in the B cell follicle with some cells in the red pulp (Fig. 6 ). Like Tg(-) λ B cells in non-bcl-2 transgenic mice are developmentally arrested as shown by decreased levels of B220 (2-fold), BALB/c mice, the Igλ ϩ B cells in bcl-2 transgenic mice are located with the remainder of the B cells, in the B cell CD21/35 (3-fold), CD22 (2-fold), CD23 (2-fold) and increased level of HSA (2-fold) (17) (Fig. 5b) . As is shown in Fig. 5(b) , follicle, with few to no B cells in the periarteriolar lymphoid sheath. A striking feature of bcl-2 Tg mice is a dramatic the presence of the bcl-2 Tgs does not alter the developmental arrest of the VH3H9/λ B cells; they still express decreased increase, compared to Tg(-) mice, in B cells (of both L chain isotypes) in the red pulp (Fig. 6 ). Previously, we have shown not alter their developmental arrest or accumulation at the T/ B interface in the spleen. that without the bcl-2 Tg, VH3H9/λ B cells localize to the T/B interface (17) . In the presence of the bcl-2 Tg, VH3H9/λ B Bcl-2 does not protect GC B cells against Fas-mediated cells are also primarily located at the T/B interface and in the death, but does protect against death-by-neglect red pulp (Fig. 6) . The localization of VH3H9/bcl-2 λ B cells is similar to that found in the HEL model where in the context
The analysis of the VH3H9/λ anti-dsDNA B cells suggests that central tolerance mechanisms to curtail anti-dsDNA B of a bcl-2 Tg (bcl-2-22) the autoreactive anti-HEL B cells persisted longer in the recipient spleens, but their localization cells are intact in the bcl-2 transgenic mice. Tolerance can also be broken in the generation of the modified repertoire, to the T/B interface was not altered (13). Therefore, although Bcl-2 increases the lifespan of anti-dsDNA B cells, it does e.g. during GC maturation. If the bcl-2 transgenic is providing Fig. 9 . Model of anti-dsDNA antibody production in bcl-2 transgenic mice. In VH3H9 transgenic mice, anti-dsDNA B cells encounter antigen in the BM. These B cells are not deleted, but enter the periphery in a functionally compromised state and have a shortened lifespan. The bcl-2 transgenic is able to protect the anti-dsDNA B cells from death, but does not affect their anergy. Non-DNA B cells in both Tg(-) and VH3H9 transgenic mice do not encounter their antigen in the BM. These cells exit to the periphery as functionally capable B cells. During an immune response, these B cells will encounter their antigen, receive T cell help and enter GC where they can undergo rounds of somatic mutation, thus altering their affinity for antigen. Some of these mutations result in antibodies that have an increased affinity for the desired antigen and these B cells receive positive signals to survive. Other mutations will lead to B cells with decreased affinity for antigen; the lack of a positive signal leads to the death of the B cells. However, a proportion of these mutations will result in B cells with reactivity to self antigens, such as dsDNA. These autoreactive B cells would normally die due to lack of a positive signal (death by neglect). In this model, Bcl-2 is able to protect these cells against death by neglect and thus allows them to survive and produce autoantibodies. a survival advantage for GC B cells, then this predicts that indeed clonally related and to identify potential somatic mutations, their H and L chain genes were sequenced. Clonal there will be less death in GC from bcl-2 Tg mice than from Tg(-) mice. To increase the frequency of GC B cells, Tg (-) relatedness was established by identical CDR3 regions (data not shown). The two hybrids expressed the same SM7/JH5 and bcl-2 transgenic mice were immunized with influenza virus (PR8) and sacrificed at day 8. Spleen sections were H chain and V κ 4/5/J κ 5 L chain gene segment combinations (22, 49) . While these H and L gene segment combinations stained by TUNEL to detect apoptotic cells within GC in situ. GC from bcl-2 transgenic mice have 50% less apoptotic cells have not been previously reported, the H chain resembles that used by a DNA-binding hybrid from an immunized bcl-2 than Tg(-) GC (Fig. 7 and Table 1 ). This is consistent with a previously published report using p-azophenylarsonatetransgenic mouse (95% identity) (50), and the L chain resembles those previously published for anti-DNA (97% immunized bcl-2 transgenic mice (36). Together, these data suggests that the bcl-2 Tg may be protecting GC B cells identity) and anti-cardiolipin (96% identity) autoantibodies from lupus-prone mice (51,52). When the sequences of the against some triggers of cell death in the GC.
GC B cells, which are normally Bcl-2 -(6,37), express a H and L chains used by the two hybridomas were compared, there was no evidence of somatic mutation. The possibility high level of Fas (Fig. 8a) (38) and have been shown to be susceptible to death triggered through Fas (39) . Because the remains, however, that the two hybrids are somatically mutated from their germline counterpart. To definitively assign the bcl-2 Tg used in this study is abnormally expressed in the GC (16), we looked to see if Bcl-2 was able to protect these contribution of somatic mutation in the generation of ANA, the germline sequence of these H and L chain genes would GC B cells against Fas-mediated death. The frequency of PNA high GC B cells from mice immunized 8 days earlier with need to be identified, and the antibody re-expressed to show that they differ from the Ig of the retrieved hybridomas and influenza was increased from 1.0 Ϯ 0.31% in naive mice to 4.6 Ϯ 1.4% after immunization (P ϭ 0.0001). As has been that they do not generate anti-dsDNA antibodies. previously reported, these PNA high B cells from Tg(-) and bcl-2 transgenic mice are Fas high (38) (Fig. 8a) . Note, however, Summary PNA low B cells express a low, but detectable, level of Fas compared to lpr/lpr B cells. The spleen cells from immunized bcl-2 transgenic mice develop anti-dsDNA autoantibodies that resemble those present in SLE. To better understand the mice were cultured in vitro for 4 h with either supernatant derived from FasL-transfected cells or mock-transfected cells.
origin of these autoantibodies, we have used a bcl-2 Tg in association with an Ig Tg that allows us to identify and track Thymocytes from Tg(-) BALB/c mice were used as a positive control and C57BL/6-lpr/lpr mice as a negative control for anti-dsDNA B cells. Previously, we have shown that one population of anti-dsDNA B cells (VH3H9/λ1) generated in Fas killing. As is shown in Fig. 8(b) , thymocytes from Fas wild-type, but not lpr/lpr mice die when cultured in FasL the BM are actively tolerized in BALB/c mice as manifested by their developmental arrest, localization to the T/B interface showing specificity of the FasL. GC B cells from Tg(-) BALB/c mice die in media alone and, because there is so much in the spleen, increased in vivo turnover rate and absence of their antibody in the serum (17) . The expression of a bcl-2 death in media alone ( Figure 8C ), it is hard to detect a significant increase in death when cultured with FasL. ImportTg increased the lifespan of these anti-dsDNA B cells, but did not alter the other features of tolerance. Importantly, their antly, the presence of the bcl-2 Tg protects the GC B cells against death in media alone. However, Bcl-2 does not protect antibody remained undetectable in the serum. These data suggest that the anergy of anti-dsDNA B cells is independent against death triggered by FasL (Fig. 8c) . The ability of Bcl-2 to block Fas-mediated death has been highly controversial of their reduced lifespan. Additionally, the effect of Bcl-2 in the induction of ANA does not occur at the level of breaking (40) (41) (42) (43) (44) (45) . Here, we show that Bcl-2 has no protective effect for GC B cells against killing through Fas. These data suggest B cell anergy, consistent with the effect of bcl-2 Tg on tolerance to model antigens (10-13). Weigert's group has that the role of Bcl-2 may be to protect GC B cells against death resulting from the absence of a positively selecting identified another population of anti-dsDNA B cells (VH3H9/ V κ 4) that, rather than being anergized, are deleted in the BM signal that is missing in the 'media alone' condition, such as T cell help (46) . (53) . The fate of these B cells in the context of a bcl-2 Tg has not been determined.
Clonal expansion of ANA B cells
Instead of a breakdown in central tolerance, ANA may arise from modifications of the primary repertoire through somatic One characteristic of cells that have transited a GC is their clonal expansion as well as the acquisition of somatic mutation in the periphery. While the bcl-2 Tg is aberrantly expressed in pre-B, immature B and GC B cells, studies from mutations (47, 48) . To determine if the ANA in bcl-2 transgenic mice arise by this mechanism, a hybridoma panel was other groups have suggested that Bcl-2 primarily affects the survival of GC B cells (36,50). Normally, B cells that have generated from the unmanipulated spleen of a bcl-2 transgenic mouse that was producing serum ANA. Twenty percent mutated toward self specificities during a GC reaction would not survive in the absence of appropriate T cell help and/ of the hybridomas recovered were ANA ϩ , consistent with the serum data. All of the hybridomas, regardless of ANA status or antigen (1,54). Aberrant Bcl-2 expression in the bcl-2 transgenic mice may protect these somatic variants from (n ϭ 43), were analyzed by Southern blot to identify potential clonally related sets. Identical Southern blot rearrangement death by neglect. While we obtained direct evidence of clonal expansion of ANA ϩ B cells, we did not identify somatic patterns of H and L chain loci were seen in two of the ANA ϩ hybridomas, suggesting that they were members of a clone mutations of their Ig to formally demonstrate GC transit. Manser's group has recovered, in hybridoma panels (data not shown). To establish that these two hybrids were (Fig. 9) .
ss single-stranded
The first is by rearrangement in the BM, as is the case for Tg transgene VH3H9/λ1. These B cells, as we have detailed in this paper, are rendered tolerant as manifested by developmental arrest References and retention at the T/B interface, both with and without the bcl-2 Tg. A second mechanism for generating ANA B cells
